The GenomeBrain platform uses machine learning to compare a patient’s personal and medical data with medical guidelines databases and available DNA test types. Within minutes, the platform provides the patient’s healthcare provider or genetic counselor with a personalized report of recommended tests.
GenomeBrain is currently optimized for use in hereditary cancer and reproductive genetic testing, with support for other disease areas such as cardiovascular health and pharmacogenomics in development.
“While the growing testing volumes signal a positive change in attitudes toward the value of genetics, we know that building the infrastructure for genetic counselors, physicians and health systems to scale genetic testing is what is needed to implement cost-effective and evidence-based personalized medicine powered by genetics,” Sanjay Sathe, GenomeSmart CEO and co-founder, said in a statement.
More articles about AI:
AI links city’s good mood days to risky behaviors
Clinc lands record-setting investment for conversational AI: 4 things to know
AI digital therapeutics startup Biofourmis raises $35M in Series B funding
